Linperlisib Combined With EZH2 Inhibitor in Relapsed/Refractory Peripheral T-cell Lymphoma (PTCL)

Linperlisib doses were preset at 40mg QD and 60mg QD, while SHR2554 doses were preset at 150mg BID, 200mg BID, and 300mg BID, forming six dose groups in total. The BOIN Waterfall design was employed to divide these six groups into two sub-trials.

Initially, three participants will be recruited into the lowest dose group of the first sub-trial: Linperlisib (40mg QD) and SHR2554 (150mg BID). After completing the dose-limiting toxicity (DLT) observation period, the next dose group will begin. Once DLT evaluations for the three participants are completed, the statistician will review the safety data and, following the decision-making flowchart of the BOIN design, determine whether to escalate to the next dose level. Another three participants will be enrolled and evaluated, continuing this process until all dose combinations in the first sub-trial have been tested, the sample size is depleted, or a stopping rule is triggered. Based on the results of the first sub-trial, the statistician will assess and select the starting dose for the second sub-trial, repeating the process until the trial is complete.

Inclusion criteria

• Age ≥18 years old, male or female;
• Pathologically confirmed PTCL, including systemic anaplastic large cell lymphoma (ALCL), peripheral T cell lymphoma non-specific type (PTCL NOS), lymph node T-follicular helper cell lymphoma (nTFHL) [including nTFHL angioimmunoblastic type (NTFHL-AI), nTFHL follicular type (NTFHL-F) and nTFHL non-specific name (NTFHL-NOS)], enteropathy-associated T-cell lymphoma and hepato-splenic T-cell lymphoma;
• Have received at least one previous systemic therapy, ALCL patients must have received CD30-targeted therapy; Patients were allowed to have received hematopoietic stem cell transplantation;
• There must be at least one evaluable lesion/measurable lesion that meets the 2014 version of Lugano lymphoma evaluation criteria [Evaluable lesion
• ECOG PS 0-2;
• Adequate organ function:
• Expected survival of at least 3 months;
• Fertile male and female subjects are willing to use effective contraceptive measures throughout the study period and for six months after the last dose.
• Volunteer to participate in clinical studies and sign informed consent, willing to follow and able to complete all trial procedures.

Exclusion criteria

If a patient has any of the following conditions should not be included in this study:

• Had been treated with PI3K inhibitor or EZH2 inhibitor or EZH1/2 inhibitor before enrollment;
• Primary cutaneous T-cell lymphoma;
• History of other primary aggressive malignancies that are not in remission or in remission for no more than 3 years;
• Involvement of the central nervous system (meninges or brain parenchyma);
• People with a known allergy to any of the drugs in the study
• Participated in other drug clinical trials within 4 weeks before the study began;
• Pregnant or lactating women;
• Active infected persons, except tumor-related B symptom fever;
• Diseases and medical history:

• have multiple factors that affect oral medication (such as inability to swallow, chronic diarrhea and intestinal obstruction);
• have a history of psychotropic substance abuse and can not quit or have mental disorders;
• Subjects with any severe and/or uncontrolled medical condition;
• A history of immunodeficiency, including HIV testing positive, or other acquired or congenital immunodeficiency diseases, or a history of organ transplantation;
• Other situations deemed unsuitable for inclusion in the study by the researcher.